Dudediligence.

Keros Therapeutics, Inc

KROSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$388,000Sep ’24$3.0MDec ’24$211.2MMar ’25$18.2MJun ’25$14.3MSep ’25$385,000Dec ’25$367,000Mar ’26$0.00Jun ’26
Net income, by quarter
−$53.0MSep ’24−$46.0MDec ’24$148.5MMar ’25−$30.7MJun ’25−$7.3MSep ’25−$23.5MDec ’25−$23.7MMar ’26−$28.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$20.1M$0.00$151,000$3.5M$244.1M
Operating income−$56.4M−$114.8M−$169.9M−$210.8M$67.6M
Net income−$58.7M−$104.7M−$153.0M−$187.4M$87.0M
Operating cash flow−$62.1M−$70.1M−$124.5M−$160.9M$107.5M
Free cash flow−$63.2M−$71.3M−$127.0M−$162.8M$106.0M
Cash$230.0M$279.0M$331.1M$559.9M$287.4M
Shares outstanding24.0M27.5M31.8M40.6M19.5M